What question did this study set out to answer?

This research aims to evaluate RNA-editing signatures as indicators of disease progression in myeloproliferative neoplasms and leukemia evolution.

April 5, 2026

Abstract 3752: RNA editing deaminase activation as a dynamic marker to track hematopoietic stem cell fitness and leukemia evolution

Key Points

This research aims to evaluate RNA-editing signatures as indicators of disease progression in myeloproliferative neoplasms and leukemia evolution.
Integrated longitudinal analyses of 150-gene next-generation sequencing for 129 MPN patients.
Assessed gene expression levels of ADAR1, APOBEC3C, STAT3, and JAK2 using qPCR on selected CD34+ cells.
Monitored dynamic changes in gene expression during treatment and disease progression.
ADAR1 and APOBEC3C expression levels increased alongside stable variant allele frequency.
High ADAR1 expression correlated with increased colony counts in survival assays.
Dynamic marker potential of ADAR1 for tracking disease progression established.

Abstract

Abstract Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell-derived disorders that can evolve into acute myeloid leukemia (AML) at variable rates. Although JAK2 inhibitor therapies have improved outcomes, and variant allele frequency (VAF) monitoring informs therapeutic response, predicting if pre-leukemic stem cells will acquire self-renewal and transform into malignant leukemia stem cells (LSCs) remains a critical challenge. Our recent studies identified inflammatory responsive RNA-editing enzymes, ADAR1 and APOBEC3C as contributors of pre-leukemic stem cell (LSC) evolution. Given that MPNs are stem cell-driven disorders, we hypothesize that RNA-editing signatures mediated by these enzymes could serve as real-time indicators to track disease progression. This study aims to integrate driver mutation VAF, ADAR1 and APOBEC3C gene expression, and RNA-editing patterns into a comprehensive biomarker tool to evaluate MPN progression, predict therapeutic response, guide clinical decision making, and prevent transformation to leukemia. We performed longitudinal 150-gene next-generation sequencing (NGS) analyses for 129 MPN patients with a median follow-up time of 958 days (range 0-4214). From this cohort, we selected four patients who were treated with the JAK2 inhibitors, progressed to sAML, underwent stem cell transplantation, and had cryopreserved peripheral blood and bone marrow mononuclear cells stored in our biorepository. For these patients, we had 15, 17, 24, and 31 sequential time points collected between 2013 and 2025. qPCR was performed on CD34+ immunomagnetic bead-selected cells to measure ADAR1, APOBEC3C, STAT3, and JAK2 expression levels. During treatment, we observed dynamic changes in ADAR1, APOBEC3C, JAK2, and STAT3 expression levels. Notably, while VAF remained stable, both lactate dehydrogenase (LDH) and ADAR1 expression levels increased. Survival and self-renewal assays comparing time points with relatively low versus high ADAR1 expression revealed significantly increased colony counts at the high-expression time points. These findings suggest that ADAR1 expression may serve as a dynamic marker for both disease progression. Further single-cell RNA sequencing studies will delineate differences in HSCs and HPCs at sequential time points for four MPN patients that progressed to sAML. Citation Format: Inge van der Werf, Jessica Pham, Neha Katragadda, Kendale Wirtjes, Athena Mohebbi, Emma Klacking, Thomas Whisenant, Ludmil B. Alexandrov, Sheldon Morris, Catriona Jamieson. RNA editing deaminase activation as a dynamic marker to track hematopoietic stem cell fitness and leukemia evolution abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 3752.

اسأل الذكاء الاصطناعي

Bookmark